Regenxbio Inc
(NAS:RGNX)
$
10
0.08 (0.81%)
Market Cap: 495.45 Mil
Enterprise Value: 320.09 Mil
PE Ratio: 0
PB Ratio: 1.64
GF Score: 65/100 Regenxbio Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022 / 06:55PM GMT
Release Date Price:
$26.82
(+1.86%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Let's go ahead and get started. Thanks, everyone, for joining. This is the fireside chat with REGENXBIO. I'm happy to have with me, Ken Mills, CEO; and Ram Palanki EVP of Commercial Strategy. Thanks for joining us again. My name is Vikram Purohit, one of the biotech analysts with Morgan Stanley Research. And before we get started, I need to read a brief disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
With that, Ken, Ram, thanks for joining. Appreciate it.
Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director
Thanks for having us.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Of course.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot